FY2024 Earnings Estimate for VRDN Issued By Leerink Partnrs

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Investment analysts at Leerink Partnrs reduced their FY2024 earnings per share (EPS) estimates for shares of Viridian Therapeutics in a note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of ($3.85) per share for the year, down from their previous forecast of ($3.83). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.94) per share. Leerink Partnrs also issued estimates for Viridian Therapeutics’ Q4 2024 earnings at ($0.88) EPS, FY2025 earnings at ($3.71) EPS, FY2026 earnings at ($3.05) EPS, FY2027 earnings at ($1.47) EPS and FY2028 earnings at $1.26 EPS.

VRDN has been the subject of a number of other reports. HC Wainwright upped their target price on Viridian Therapeutics from $27.00 to $34.00 and gave the company a “buy” rating in a research report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research report on Wednesday. Royal Bank of Canada reissued an “outperform” rating and issued a $44.00 target price on shares of Viridian Therapeutics in a research report on Thursday, September 19th. BTIG Research upped their target price on Viridian Therapeutics from $56.00 to $61.00 and gave the company a “buy” rating in a research report on Thursday, September 26th. Finally, The Goldman Sachs Group upped their target price on Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, September 12th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.33.

Viridian Therapeutics Trading Down 3.7 %

NASDAQ:VRDN opened at $21.64 on Friday. The stock has a 50-day simple moving average of $22.35 and a 200-day simple moving average of $16.89. The stock has a market cap of $1.71 billion, a P/E ratio of -5.02 and a beta of 1.10. Viridian Therapeutics has a 1 year low of $11.40 and a 1 year high of $27.20. The company has a debt-to-equity ratio of 0.05, a quick ratio of 15.82 and a current ratio of 15.82.

Institutional Investors Weigh In On Viridian Therapeutics

Large investors have recently bought and sold shares of the stock. Hennion & Walsh Asset Management Inc. grew its holdings in Viridian Therapeutics by 62.9% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 178,855 shares of the company’s stock valued at $2,327,000 after buying an additional 69,035 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Viridian Therapeutics by 34.5% during the second quarter. Rhumbline Advisers now owns 90,826 shares of the company’s stock worth $1,182,000 after purchasing an additional 23,305 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Viridian Therapeutics by 7.8% during the first quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock worth $56,632,000 after purchasing an additional 233,331 shares during the last quarter. Candriam S.C.A. boosted its holdings in shares of Viridian Therapeutics by 167.8% during the second quarter. Candriam S.C.A. now owns 749,804 shares of the company’s stock worth $9,754,000 after purchasing an additional 469,804 shares during the last quarter. Finally, Novo Holdings A S boosted its holdings in shares of Viridian Therapeutics by 19.3% during the third quarter. Novo Holdings A S now owns 2,385,000 shares of the company’s stock worth $54,259,000 after purchasing an additional 385,000 shares during the last quarter.

Insider Buying and Selling at Viridian Therapeutics

In related news, COO Thomas W. Beetham bought 5,000 shares of the stock in a transaction on Friday, September 27th. The shares were purchased at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the acquisition, the chief operating officer now owns 6,000 shares in the company, valued at $140,460. This represents a 500.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Fairmount Funds Management Llc bought 1,600,000 shares of the stock in a transaction on Friday, September 13th. The shares were bought at an average price of $18.75 per share, for a total transaction of $30,000,000.00. Following the acquisition, the director now owns 3,445,813 shares in the company, valued at $64,608,993.75. The trade was a 86.68 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 1,626,400 shares of company stock worth $30,616,312. 0.65% of the stock is owned by insiders.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.